Trials / Withdrawn
WithdrawnNCT01103024
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AIN457 | |
| BIOLOGICAL | AIN457 | |
| BIOLOGICAL | AIN457 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-04-13
- Last updated
- 2020-09-29
Locations
11 sites across 5 countries: United States, Canada, Israel, Japan, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01103024. Inclusion in this directory is not an endorsement.